Compare FTAIN & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
FTAI Aviation Ltd. 8.25% Fixed - Rate Reset Series C Cumulative Perpetual Redeemable Preferred Shares
Current Price
Current Price
| Metric | FTAIN | XGN |
|---|---|---|
| Founded | N/A | 2002 |
| Country | United States | United States |
| Employees | 580 | N/A |
| Industry | Misc Corporate Leasing Services | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 138.9M |
| IPO Year | N/A | 2019 |
| Metric | FTAIN | XGN |
|---|---|---|
| Price | $25.33 | $6.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $13.67 |
| AVG Volume (30 Days) | N/A | ★ 295.4K |
| Earning Date | N/A | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $63,599,000.00 |
| Revenue This Year | N/A | $21.76 |
| Revenue Next Year | N/A | $15.63 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 14.08 |
| 52 Week Low | N/A | $2.67 |
| 52 Week High | N/A | $12.23 |
| Indicator | FTAIN | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 47.75 | 28.31 |
| Support Level | $25.33 | $5.84 |
| Resistance Level | $25.53 | $6.34 |
| Average True Range (ATR) | 0.10 | 0.33 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 53.32 | 18.97 |
FTAI Aviation Ltd is an aerospace company. It owns and maintains commercial jet engines with a focus on CFM56 engines. FTAI owns and leases jet aircraft, which often facilitates the acquisition of engines at attractive prices. It invests in aviation assets and aerospace products that generate stable cash flows with the potential for earnings growth and asset appreciation.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.